Pioglitazone Actavis
Oral antidiabetic medication for type 2 diabetes mellitus
Quick Facts About Pioglitazone Actavis
Key Takeaways About Pioglitazone Actavis
- Reduces insulin resistance: Pioglitazone helps your body use its own insulin more effectively, improving blood sugar control in type 2 diabetes
- Takes 3–6 months for full effect: Your doctor will evaluate effectiveness after this period; some improvement may occur earlier
- Not for everyone: Do not take if you have heart failure, liver disease, diabetic ketoacidosis, or history of bladder cancer
- Monitor for side effects: Watch for rapid weight gain, swelling, breathlessness (heart failure signs), and blurred vision
- Bone fracture risk: Higher fracture rates reported, particularly in women; discuss your risk with your doctor
What Is Pioglitazone Actavis and What Is It Used For?
Pioglitazone Actavis contains the active substance pioglitazone, a thiazolidinedione (glitazone) used to treat type 2 diabetes mellitus. It reduces insulin resistance in peripheral tissues and the liver, enabling the body to use its own insulin more effectively to control blood sugar levels.
Type 2 diabetes mellitus, also known as non-insulin-dependent diabetes, typically develops in adulthood and is characterised by the body's inability to properly use the insulin it produces. This condition is called insulin resistance, and it leads to elevated blood glucose levels that, if left untreated, can cause serious long-term complications affecting the heart, kidneys, eyes, and nerves.
Pioglitazone Actavis works by activating a specific receptor called peroxisome proliferator-activated receptor gamma (PPAR-gamma). When this receptor is activated, it improves insulin sensitivity in fat tissue, skeletal muscle, and the liver. This means your body can use its own insulin more efficiently, leading to better blood sugar control without directly stimulating insulin production. The mechanism of action is fundamentally different from sulfonylureas or insulin, which either increase insulin secretion or provide external insulin.
This medication may be prescribed in several clinical scenarios. It can be used as monotherapy in patients who cannot take metformin (for example, due to kidney impairment or intolerance) and for whom diet and exercise alone have not achieved adequate glycaemic control. More commonly, pioglitazone is used as an add-on therapy in combination with metformin, a sulfonylurea, or insulin when these treatments alone have been insufficient. Clinical trials have demonstrated that pioglitazone reduces HbA1c (a measure of long-term blood sugar control) by approximately 0.5% to 1.5% depending on the dose and combination used.
After starting treatment, your doctor will typically assess whether pioglitazone is working effectively for you after 3 to 6 months. This evaluation period is necessary because the medication's full glucose-lowering effect develops gradually as insulin sensitivity improves across different tissues. If the desired reduction in blood sugar has not been achieved after this period, your treatment plan may need to be adjusted.
Unlike metformin (which primarily reduces glucose production in the liver) or sulfonylureas (which stimulate the pancreas to produce more insulin), pioglitazone works by making your body's cells more responsive to insulin. This unique mechanism can provide complementary benefits when used alongside other diabetes treatments. Additionally, pioglitazone has been shown to have favourable effects on blood lipid profiles, increasing HDL cholesterol and reducing triglycerides.
What Should You Know Before Taking Pioglitazone Actavis?
Do not take Pioglitazone Actavis if you have heart failure, liver disease, diabetic ketoacidosis, bladder cancer (current or history), or unexplained blood in urine. Tell your doctor about all medical conditions and medications before starting treatment.
Contraindications
There are several important situations in which you must not take Pioglitazone Actavis. These contraindications are absolute, meaning the medication should never be used in these circumstances:
- Allergy to pioglitazone or any of the inactive ingredients in the formulation, including lactose monohydrate, hydroxypropylcellulose, calcium carmellose, and magnesium stearate
- Heart failure (current or history) – pioglitazone causes fluid retention that can worsen heart failure or trigger it in susceptible individuals
- Liver disease – pioglitazone is metabolised in the liver, and impaired liver function can lead to dangerous accumulation of the drug
- Diabetic ketoacidosis – a serious complication of diabetes that requires emergency treatment with insulin, not oral antidiabetic agents
- Bladder cancer (active or history) – epidemiological studies have suggested a possible increased risk of bladder cancer with pioglitazone use
- Uninvestigated haematuria (blood in urine) – this symptom must be investigated before starting treatment, as it could indicate bladder cancer
Warnings and Precautions
Several conditions require special caution and close monitoring when using pioglitazone. Discuss these with your doctor before starting treatment:
Fluid retention and heart failure: Pioglitazone can cause fluid retention (oedema), which may worsen or trigger heart failure, especially in patients over 75 years of age. The risk is highest when pioglitazone is combined with insulin. Some patients with long-standing type 2 diabetes and pre-existing cardiovascular disease have developed heart failure when treated with pioglitazone plus insulin. Seek immediate medical attention if you experience unexpected breathlessness, rapid weight gain, or localised swelling (oedema).
Macular oedema: If you have a type of diabetic eye disease called macular oedema (swelling at the back of the eye causing blurred vision), inform your doctor. Cases of new or worsening macular oedema have been reported with pioglitazone use. Contact your doctor promptly if you experience blurred vision or visual disturbances for the first time, or if existing symptoms worsen.
Bone fractures: An increased rate of bone fractures has been observed in patients taking pioglitazone, particularly in women. The fractures predominantly affect the upper limbs (forearms, hands) and lower limbs (feet, ankles, legs). Your doctor will consider this risk when managing your diabetes treatment, especially if you already have osteoporosis or other risk factors for fractures.
Polycystic ovary syndrome (PCOS): Women with ovarian cysts may experience a return of ovulation when taking pioglitazone, which could increase the chance of pregnancy. If this applies to you, use appropriate contraception to avoid unplanned pregnancy.
Liver monitoring: Before starting pioglitazone, your doctor will perform blood tests to check your liver function. These tests may be repeated at intervals during treatment. If you develop symptoms suggestive of liver problems (unexplained nausea, vomiting, abdominal pain, fatigue, dark urine), contact your doctor immediately.
Contact your doctor immediately if you experience any of the following symptoms during treatment: unexpected shortness of breath, rapid weight gain (more than 2–3 kg in a week), or swelling in the ankles, feet, or legs. These may be signs of heart failure, which requires prompt medical evaluation. The risk is higher when pioglitazone is used in combination with insulin.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before taking Pioglitazone Actavis. Your doctor will advise you to stop taking this medication during pregnancy and breastfeeding, as the safety of pioglitazone has not been established in these situations. Alternative diabetes treatments that have a better-established safety profile during pregnancy should be used instead.
Driving and operating machinery: Pioglitazone does not directly affect the ability to drive or operate machinery. However, exercise caution if you experience visual disturbances, and be aware that hypoglycaemia (low blood sugar) can occur when pioglitazone is combined with other antidiabetic medications, which may impair your ability to drive safely.
Lactose content: Pioglitazone Actavis tablets contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to certain sugars, consult your doctor before taking this medicine.
How Does Pioglitazone Actavis Interact with Other Drugs?
Pioglitazone interacts significantly with gemfibrozil (which increases pioglitazone levels) and rifampicin (which decreases its effectiveness). When combined with insulin or sulfonylureas, the risk of hypoglycaemia increases. Always inform your doctor about all medications you take.
Drug interactions can alter how pioglitazone works or increase the risk of side effects. While you can generally continue most medications alongside pioglitazone, certain combinations require dose adjustments or enhanced monitoring. Always tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including over-the-counter medications and herbal supplements.
Major Interactions
| Interacting Drug | Effect | Clinical Significance | Action Required |
|---|---|---|---|
| Gemfibrozil | Increases pioglitazone blood levels by inhibiting CYP2C8 metabolism | High – up to 3-fold increase in pioglitazone exposure | Dose reduction of pioglitazone may be needed; close monitoring |
| Rifampicin | Decreases pioglitazone blood levels by inducing CYP2C8 metabolism | High – can reduce pioglitazone effectiveness by 54% | Blood glucose monitoring; dose increase may be needed |
| Insulin | Increased risk of hypoglycaemia and fluid retention/heart failure | High – heart failure risk significantly increased | Monitor for oedema and heart failure; insulin dose reduction |
| Sulfonylureas (e.g. glibenclamide, gliclazide) | Increased risk of hypoglycaemia | Moderate – additive glucose-lowering effect | Sulfonylurea dose reduction may be needed |
Minor Interactions
Pioglitazone is primarily metabolised by the cytochrome P450 enzyme CYP2C8, with minor contributions from CYP3A4. Other inhibitors or inducers of these enzymes may theoretically alter pioglitazone levels, though clinically significant interactions beyond those listed above are uncommon. Importantly, pioglitazone does not appear to significantly affect the metabolism of other commonly used medications, including oral contraceptives, digoxin, warfarin, or statins.
Anti-inflammatory medications (NSAIDs) deserve special mention because they can independently cause fluid retention. When combined with pioglitazone, which also causes fluid retention, the risk of oedema and swelling may be increased. Inform your doctor if you regularly use NSAIDs such as ibuprofen or naproxen.
What Is the Correct Dosage of Pioglitazone Actavis?
The usual starting dose is 15 mg or 30 mg pioglitazone once daily, which may be increased to a maximum of 45 mg once daily. Take the tablet with a glass of water, with or without food. Always follow your doctor's specific dosing instructions.
Always take Pioglitazone Actavis exactly as your doctor or pharmacist has told you. Do not change your dose without consulting your doctor first. If you feel that the effect of the medication is too weak, speak with your doctor rather than increasing the dose yourself.
Adults
Standard Adult Dosing
Starting dose: 15 mg or 30 mg once daily
Dose adjustment: May be increased gradually based on blood sugar response
Maximum dose: 45 mg once daily
Administration: Take with a glass of water, with or without food, at approximately the same time each day
When pioglitazone is used in combination with other diabetes medications (such as metformin, sulfonylureas, or insulin), your doctor will determine whether the dose of your other medications needs to be reduced to prevent hypoglycaemia. Your blood sugar will be monitored regularly through blood tests, and your doctor may also check your liver function at intervals during treatment.
It is important to continue following any dietary recommendations for diabetes management while taking pioglitazone. Regular weight monitoring is also advisable, and you should inform your doctor if you notice significant weight gain.
Children
Pioglitazone Actavis is not recommended for children and adolescents under 18 years of age. The safety and efficacy of pioglitazone have not been established in paediatric populations, and there are no data to support its use in this age group.
Elderly
No dose adjustment is required solely based on age. However, elderly patients (especially those over 75 years) may be at increased risk for fluid retention and heart failure. Your doctor will start treatment with the lowest effective dose and monitor you closely for signs of fluid accumulation, cardiac symptoms, and bone fracture risk.
Missed Dose
If you forget to take a dose, simply take your next scheduled dose at the usual time. Do not take a double dose to make up for a missed tablet. For blister packs with 14, 28, 56, 84, or 98 tablets, you can check which day you last took a tablet by referring to the calendar printed on the blister strip, which shows the days of the week.
Overdose
If you accidentally take too many tablets, or if someone else or a child takes your medicine, contact a doctor or pharmacist immediately. Your blood sugar may drop below normal levels, which can be corrected by consuming sugar (sugar cubes, sweets, biscuits, or sweetened fruit juice). It is advisable to carry sugar-containing items with you at all times while taking antidiabetic medications.
Pioglitazone Actavis should be taken daily to achieve the desired therapeutic effect. If you stop taking the medication, your blood sugar levels may increase. Always consult your doctor before stopping or changing your treatment regimen.
What Are the Side Effects of Pioglitazone Actavis?
Common side effects include upper respiratory infections, weight gain, numbness or tingling, and visual disturbances. Serious side effects to watch for include heart failure (breathlessness, rapid weight gain, swelling), bladder cancer signs, bone fractures, and macular oedema.
Like all medicines, Pioglitazone Actavis can cause side effects, although not everybody gets them. Some side effects are serious and require immediate medical attention, while others are mild and may resolve as your body adjusts to the medication.
Serious Side Effects Requiring Immediate Attention
Heart failure: Heart failure has been commonly reported (up to 1 in 10 people) when pioglitazone is used in combination with insulin. Symptoms include unusual breathlessness, rapid weight gain, and localised swelling (oedema). Seek immediate medical attention if you experience any of these, particularly if you are over 65 years of age.
Bladder cancer: Bladder cancer has been reported in some patients (up to 1 in 100 people) taking pioglitazone. Signs include blood in your urine, pain during urination, or sudden urges to urinate. Contact your doctor as soon as possible if you notice any of these symptoms.
Macular oedema: Blurred vision due to swelling or fluid at the back of the eye has been reported (frequency unknown). Contact your doctor promptly if you experience this for the first time, or if existing blurred vision worsens.
Allergic reactions: Severe allergic reactions including hives, swelling of the face, lips, tongue, or throat (which can cause difficulty breathing or swallowing) have been reported (frequency unknown). Stop taking the medication and contact your doctor immediately if this occurs.
Side Effect Frequency Overview
Very Common (more than 1 in 10 people)
When used with other diabetes medicines
- Hypoglycaemia (low blood sugar)
Common (up to 1 in 10 people)
May affect up to 1 in 10 patients
- Upper respiratory tract infection
- Visual disturbances
- Weight gain
- Numbness or tingling (paraesthesia)
- Headache
- Dizziness
- Joint pain (arthralgia)
- Erectile dysfunction
- Back pain
- Shortness of breath
- Slight reduction in red blood cells (anaemia)
- Flatulence
- Heart failure (with insulin combination)
- Oedema/swelling (with insulin combination)
- Bone fractures (especially in women)
Uncommon (up to 1 in 100 people)
May affect up to 1 in 100 patients
- Sinusitis
- Insomnia
- Sugar in urine (glycosuria)
- Protein in urine (proteinuria)
- Elevated liver enzymes
- Vertigo
- Excessive sweating
- Fatigue
- Increased appetite
- Bladder cancer
Frequency Not Known
Cannot be estimated from available data
- Elevated liver enzymes
- Allergic reactions (urticaria, angioedema)
- Macular oedema (blurred vision)
- Bone fractures in men
It is important to report suspected side effects after the medicine has been authorised. This allows for continuous monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national medicines regulatory authority (such as the FDA in the United States, EMA in Europe, or MHRA in the United Kingdom).
How Should You Store Pioglitazone Actavis?
Store Pioglitazone Actavis out of the sight and reach of children. No special storage conditions are required. Do not use after the expiry date printed on the packaging.
Proper storage of your medication ensures that it remains effective and safe throughout its shelf life. Follow these guidelines to store Pioglitazone Actavis correctly:
- Keep out of sight and reach of children at all times to prevent accidental ingestion
- Check the expiry date printed on the carton and blister pack after "EXP". The expiry date refers to the last day of the stated month. Do not use the medicine after this date
- No special storage conditions are necessary for this medicine – store at room temperature
- Disposal: Do not throw unused medicines into wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment
What Does Pioglitazone Actavis Contain?
Each tablet contains pioglitazone (as hydrochloride) in 15 mg, 30 mg, or 45 mg strengths. Inactive ingredients include lactose monohydrate, hydroxypropylcellulose, calcium carmellose, and magnesium stearate.
Active Ingredient
The active substance is pioglitazone, present in the form of pioglitazone hydrochloride. Each tablet is available in three strengths: 15 mg, 30 mg, or 45 mg of pioglitazone.
Inactive Ingredients (Excipients)
- Lactose monohydrate
- Hydroxypropylcellulose
- Calcium carmellose
- Magnesium stearate
Tablet Appearance
| Strength | Appearance | Diameter | Engraving |
|---|---|---|---|
| 15 mg | White, round, flat, bevelled | 5.5 mm | TZ15 on one side |
| 30 mg | White, round, flat, bevelled | 7 mm | TZ30 on one side |
| 45 mg | White, round, flat, bevelled | 8 mm | TZ45 on one side |
Pioglitazone Actavis tablets are supplied in aluminium blister packs containing 14, 28, 30, 50, 56, 84, 90, 98, or 100 tablets. The 14, 28, 56, 84, and 98 tablet packs include blisters printed with abbreviated weekday names (Mon, Tue, Wed, Thu, Fri, Sat, Sun) to help you track your daily doses. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Pioglitazone Actavis
Pioglitazone Actavis is used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels by reducing insulin resistance, which means your body can use its own insulin more effectively. It can be used alone when metformin is not suitable, or in combination with metformin, sulfonylureas (such as glibenclamide or gliclazide), or insulin when these treatments alone have not provided adequate blood sugar control.
Pioglitazone may take 3 to 6 months to reach its full therapeutic effect. While some blood sugar improvement may be noticeable within a few weeks, the maximum glucose-lowering effect develops gradually as insulin sensitivity improves in fat tissue, muscle, and the liver. Your doctor will evaluate the medication's effectiveness after this initial period and adjust your treatment if necessary.
The most serious side effects include heart failure (especially when combined with insulin, with symptoms such as unexpected breathlessness, rapid weight gain, and swelling), bladder cancer risk (signs include blood in urine, pain during urination, or urinary urgency), bone fractures (particularly in women), and macular oedema (blurred vision from swelling at the back of the eye). If you experience any of these symptoms, contact your doctor immediately.
Yes, weight gain is a common side effect of pioglitazone. This occurs through two mechanisms: fluid retention (oedema) and increased fat accumulation in subcutaneous tissue. Your doctor will monitor your weight regularly during treatment. If you experience significant or rapid weight gain, report it to your healthcare provider promptly, as it could also indicate fluid retention or early signs of heart failure.
Pioglitazone should not be taken by people with heart failure (current or past), liver disease, diabetic ketoacidosis, active or previous bladder cancer, or unexplained blood in urine. It is not recommended for children under 18 years of age. Pregnant and breastfeeding women should not use this medication. People who are allergic to pioglitazone or any of the inactive ingredients (including lactose) should also avoid it.
Yes, pioglitazone has clinically significant interactions with several medications. Gemfibrozil can increase pioglitazone levels up to 3-fold, while rifampicin can reduce its effectiveness by about 54%. When combined with insulin or sulfonylureas, the risk of hypoglycaemia (low blood sugar) increases, and insulin combinations also carry a higher risk of heart failure. Always inform your doctor about all medications you are taking.
References and Sources
- European Medicines Agency (EMA). Pioglitazone – Summary of Product Characteristics. Last updated 2024. Available at: www.ema.europa.eu
- Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. The Lancet. 2005;366(9493):1279-1289.
- American Diabetes Association. Standards of Medical Care in Diabetes – 2025. Diabetes Care. 2025;48(Supplement 1).
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management (NG28). Updated 2024. Available at: www.nice.org.uk/guidance/ng28
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023. Available at: www.who.int
- U.S. Food and Drug Administration (FDA). Pioglitazone Prescribing Information. Available at: www.fda.gov
- Liao HW, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927.
- British National Formulary (BNF). Pioglitazone. Available at: bnf.nice.org.uk
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians in endocrinology, clinical pharmacology, and internal medicine. All medical content follows international guidelines from the WHO, EMA, FDA, NICE, and the American Diabetes Association. Our editorial process includes multi-step fact-checking and peer review according to the GRADE evidence framework.
Evidence Level
Level 1A – Based on systematic reviews and meta-analyses of randomized controlled trials
Editorial Standards
No commercial funding. Independent editorial content following GRADE methodology